Abstract
Adoptive immune cell therapy represents one of the most promising fields of investigation in allogeneic haematopoietic stem cell transplantation (allo-HSCT). Preliminary studies indicate that adoptive immune cell therapy can be used to restore the immunocompetence of allo-HSCT recipients towards widespread pathogens in the early post-transplant period. These strategies can be of fundamental importance in patients given a T-cell-depleted allograft, a type of transplant that has been performed increasingly over the last few years. A few seminal studies have recently documented that prevention/treatment of Epstein-Barr-virus-related lymphoproliferative disorders, human cytomegalovirus disease and invasive aspergillosis can be obtained through infusion of pathogen-specific T-cell lines or clones. Several efforts are also being directed towards the identification of strategies capable of selecting and/or strengthening specific graft-vs-leukaemia responses. In this regard, strategies of ex-vivo generation and expansion of clones or cell lines, specifically or preferentially leukaemia reactive, have been developed.
| Original language | English |
|---|---|
| Pages (from-to) | 479-492 |
| Number of pages | 14 |
| Journal | Best Practice and Research: Clinical Haematology |
| Volume | 17 |
| Issue number | 3 SPEC.ISS. |
| DOIs | |
| Publication status | Published - Sep 2004 |
Fingerprint
Keywords
- Adoptive cell therapy
- Allogeneic haematopoietic stem cell transplantation
- DLI
- EBV-related lymphoproliferative disorders
- HCMV infection
- Invasive aspergillosis
- Leukaemia relapse
- minimal residual disease
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Innovative approaches of adoptive immune cell therapy in paediatric recipients of haematopoietic stem cell transplantation. / Locatelli, Franco; Comoli, Patrizia; Montagna, Daniela; Rossi, Francesca; Daudt, Liane; Maccario, Rita.
In: Best Practice and Research: Clinical Haematology, Vol. 17, No. 3 SPEC.ISS., 09.2004, p. 479-492.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Innovative approaches of adoptive immune cell therapy in paediatric recipients of haematopoietic stem cell transplantation
AU - Locatelli, Franco
AU - Comoli, Patrizia
AU - Montagna, Daniela
AU - Rossi, Francesca
AU - Daudt, Liane
AU - Maccario, Rita
PY - 2004/9
Y1 - 2004/9
N2 - Adoptive immune cell therapy represents one of the most promising fields of investigation in allogeneic haematopoietic stem cell transplantation (allo-HSCT). Preliminary studies indicate that adoptive immune cell therapy can be used to restore the immunocompetence of allo-HSCT recipients towards widespread pathogens in the early post-transplant period. These strategies can be of fundamental importance in patients given a T-cell-depleted allograft, a type of transplant that has been performed increasingly over the last few years. A few seminal studies have recently documented that prevention/treatment of Epstein-Barr-virus-related lymphoproliferative disorders, human cytomegalovirus disease and invasive aspergillosis can be obtained through infusion of pathogen-specific T-cell lines or clones. Several efforts are also being directed towards the identification of strategies capable of selecting and/or strengthening specific graft-vs-leukaemia responses. In this regard, strategies of ex-vivo generation and expansion of clones or cell lines, specifically or preferentially leukaemia reactive, have been developed.
AB - Adoptive immune cell therapy represents one of the most promising fields of investigation in allogeneic haematopoietic stem cell transplantation (allo-HSCT). Preliminary studies indicate that adoptive immune cell therapy can be used to restore the immunocompetence of allo-HSCT recipients towards widespread pathogens in the early post-transplant period. These strategies can be of fundamental importance in patients given a T-cell-depleted allograft, a type of transplant that has been performed increasingly over the last few years. A few seminal studies have recently documented that prevention/treatment of Epstein-Barr-virus-related lymphoproliferative disorders, human cytomegalovirus disease and invasive aspergillosis can be obtained through infusion of pathogen-specific T-cell lines or clones. Several efforts are also being directed towards the identification of strategies capable of selecting and/or strengthening specific graft-vs-leukaemia responses. In this regard, strategies of ex-vivo generation and expansion of clones or cell lines, specifically or preferentially leukaemia reactive, have been developed.
KW - Adoptive cell therapy
KW - Allogeneic haematopoietic stem cell transplantation
KW - DLI
KW - EBV-related lymphoproliferative disorders
KW - HCMV infection
KW - Invasive aspergillosis
KW - Leukaemia relapse
KW - minimal residual disease
UR - http://www.scopus.com/inward/record.url?scp=7744245805&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=7744245805&partnerID=8YFLogxK
U2 - 10.1016/j.beha.2004.06.0054
DO - 10.1016/j.beha.2004.06.0054
M3 - Article
C2 - 15498718
AN - SCOPUS:7744245805
VL - 17
SP - 479
EP - 492
JO - Best Practice and Research in Clinical Haematology
JF - Best Practice and Research in Clinical Haematology
SN - 1521-6926
IS - 3 SPEC.ISS.
ER -